Obesity and psoriasis: Inflammatory nature of obesity, relationship between psoriasis and obesity, and therapeutic implications;Obesidad y psoriasis: naturaleza inflamatoria de la obesidad, relación entre psoriasis y obesidad e implicaciones terapéuticas

Actas Dermo-Sifiliograficas

Volumn 105, Issue 1, 2014, Pages 31-44

  Carrascosa, J M ^a   Rocamora, V ^b   Fernandez Torres, R M ^c   Jimenez Puya, R ^d   Moreno, J C ^d   Coll Puigserver, N ^b   Fonseca, E ^c  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL DE MANACOR   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL UNIVERSITARIO REINA SOFÍA   (Spain)

Author keywords

Adipokine; Metabolic syndrome; Obesity; Psoriasis; Therapy

Indexed keywords

ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; METABOLIC SYNDROME X; OBESITY; PSORIASIS; ADIPOCYTE; ADIPOSE TISSUE; BIOLOGICAL MODEL; CARDIOVASCULAR DISEASES; CELL COMMUNICATION; COMPLICATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFECTS; ECONOMICS; EPIDEMIOLOGY; HUMAN; IMMUNOLOGY; INFLAMMATION; LYMPHOCYTE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PUVA; SECRETION (PROCESS);

ADIPOCYTOKINE; ANTIINFLAMMATORY AGENT; ANTIRHEUMATIC AGENT; CELL ADHESION MOLECULE; CYTOKINE; FATTY ACID; HORMONE; IMMUNOLOGIC FACTOR;

ADIPOCYTES; ADIPOKINES; ADIPOSE TISSUE; ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; BODY WEIGHT; CARDIOVASCULAR DISEASES; CAUSALITY; CELL ADHESION MOLECULES; CELL COMMUNICATION; CYTOKINES; DISEASE SUSCEPTIBILITY; DOSE-RESPONSE RELATIONSHIP, DRUG; FATTY ACIDS, NONESTERIFIED; HORMONES; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; LYMPHOCYTES; METABOLIC SYNDROME X; MODELS, BIOLOGICAL; OBESITY; PSORIASIS; PUVA THERAPY;

EID: 84893122908     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.ad.2012.08.003     Document Type: Short Survey

References (138)

1. K. Samaras, P.J. Kelly, M.N. Chiano, T.D. Spector, and L.V. Campbell Genetic and environmental influences on total-body and central abdominal fat: the effect of physical activity in female twins Ann Intern Med 130 1999 873 882
2. WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization; 1995 [consultado Mar 2012]. Disponible en: http://whqlibdoc.who.int/trs/WHO TRS 854.pdf
3. The World Health Report 2002 Reducing risks, promoting healthy life 2002 World Health Organization Geneva, Switzerland
4. T. Henseler, and E. Christophers Disease concomitance in psoriasis J Am Acad Dermatol 32 1995 982 986
5. B. Lindegard Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes Dermatologica 172 1986 298 304
6. M. Heron, M. Hinckley, M. Hoffman, J. Papenfuss, C. Hansen, and C. Callis et al. Impact of obesity and smoking on psoriasis presentation and management Arch Dermatol 141 2005 1527 1534
7. M. Rubio, A. Gómez de la Cámara, J. del Campo, C. Jurado, J. García, and J. Gómez-Gerique et al. Prevalencia de obesidad en España tras 14 años de seguimiento de la cohorte DRECE Endocr Nutr 53 2006 83
8. M. Guerre-Millo Adipose tissue and adipokines: for better or worse Diabetes Metab 30 2004 13 19
9. T. Ronti, G. Lupattelli, and E. Mannarino The endocrine function of adipose tissue: an update Clin Endocrinol (Oxf) 64 2006 355 365
10. H. Xu, G.T. Barnes, Q. Yang, G. Tan, D. Yang, and C.J. Chou et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance J Clin Invest 112 2003 1821 1830
11. C.M. Pond Paracrine interactions of mammalian adipose tissue J Exp Zool A Comp Exp Biol 295 2003 99 110
12. N. Rasouli, and P.A. Kern Adipocytokines and the metabolic complications of obesity adipocytokines and the metabolic complications of obesity J Clin Endocrinol Metab 93 2008 S64 S73
13. T.J. Guzik, D. Mangalat, and R. Korbut Adipocytokines -novel link between inflammation and vascular function J Physiol Pharmacol 57 2006 505 528
14. S.P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, and R.L. Leibel Obesity is associated with macrophage accumulation in adipose tissue J Clin Invest 112 2003 1796 1808
15. S. Gerdes, M. Rostami-Yazdi, and U. Mrowietz Adipokines and psoriasis Exp Dermatol 20 2011 81 87
16. D.R. Gable, S.J. Hurel, and S.E. Humphries Adiponectin and its gene variants as risk factors for insulin resistance, the metabolic syndrome and cardiovascular disease Atherosclerosis 188 2006 231 244
17. M. Cnop, P.J. Havel, K.M. Utzschneider, and D.B. Carr Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex Diabetologia 46 2003 459 469
18. Y. Arita, S. Kihara, N. Ouchi, M. Takahashi, K. Maeda, and J. Miyagawa Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity Biochem Biophys Res Commun 257 1999 79 83
19. Y. Okamoto, S. Kihara, T. Funahashi, Y. Matsuzawa, and P. Libby Adiponectin: a key adipocytokine in metabolic syndrome Clin Sci (Lond) 110 2006 267 278
20. G. Fantuzzi Adiponectin and inflammation: consensus and controversy J Allergy Clin Immunol 121 2008 326 330
21. A. Koerner, J. Kratzsch, and W. Kiess Adipocytokines: leptin -the classical, resistin-the controversical, adiponectin-the promising, and more to come Best Pract Res Clin Endocrinol Metab 19 2005 525 546
22. M.W. Schwartz, S.C. Woods, D. Porte Jr., R.J. Seeley, and D.G. Baskin Central nervous system control of food intake Nature 404 2000 661 671
23. Y. Wang, J. Chen, Y. Zhao, L. Geng, and F. Song Chen HD.Psoriasis is associated with increased levels of serum leptin Br J Dermatol 158 2008 1134 1135
24. I.S. Farooqi, S.A. Jebb, G. Langmack, E. Lawrence, and C.H. Cheetham Effects of recombinant leptin therapy in a child with congenital leptin deficiency N Engl J Med 341 1999 879 884
25. I.S. Farooqi, G. Matarese, G.M. Lord, J.M. Keogh, and E. Lawrence Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine/metabolic dysfunction of human congenital leptin deficiency Clin Invest 110 2002 1093 1103
26. M. Ciccone, R. Vettor, N. Pannacciulli, A. Minenna, and M. Bellacicco Plasma leptin is independently associated with the intima-media thickness of the common carotid artery Int J Obes Relat Metab Disord 25 2001 805 810
27. R. Wolk, P. Berger, R.J. Lennon, E.S. Brilakis, B.D. Johnson, and V.K. Somers Plasma leptin and prognosis in patients with established coronary atherosclerosis J Am Coll Cardiol 44 2004 1819 1824
28. A.M. Wallace, A.D. McMahon, C.J. Packard, A. Kelly, J. Shepherd, and A. Gaw et al. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS) Circulation 104 2001 3052 3056
29. K. Schäfer, M. Halle, C. Goeschen, C. Dellas, M. Pynn, and D.J. Loskutoff et al. Leptin promotes vascular remodeling and neointimal growth in mice Arterioscler Thromb Vasc Biol 24 2004 112 117
30. P.F. Bodary, R.J. Westrick, K.J. Wickenheiser, Y. Shen, and D.T. Eitzman Effect of leptin on arterial thrombosis following vascular injury in mice JAMA 287 2002 1706 1709
31. S. Loffreda, S.Q. Yang, H.Z. Lin, C.L. Karp, M.L. Brengman, and D.J. Wang et al. Leptin regulates proinflammatory immune responses FASEB J 12 1998 57 65
32. H. Zarkesh-Esfahani, G. Pockley, R.A. Metcalfe, and M. Bidlingmaier High-dose leptin activates human leukocytes via receptor expression on monocytes J Immunol 167 2001 4593 4599
33. A.A. Cerman, S. Bozkurt, A. Sav, A. Tulunay, M.O. Elbaşi, and T. Ergun Serum leptin levels, skin leptin and leptin receptor expression in psoriasis Br J Dermatol 159 2008 820 826
34. E.A. Hamminga, A.J. van der Lely, H.A. Neumann, and H.B. Thio Chronic inflammation in psoriasis and obesity: implications for therapy Med Hypotheses 67 2006 768 773
35. C.A. Curat, V. Wegner, C. Sengenès, A. Miranville, C. Tonus, and R. Busse Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin Diabetologia 49 2006 744 747
36. M. Filková, M. Haluzík, S. Gay, and L. Senolt The role of resistin as a regulator of inflammation: Implications for various human pathologies Clin Immunol 133 2009 157 170
37. M.P. Reilly, M. Lehrke, M.L. Wolfe, A. Rohatgi, M.A. Lazar, and D.J. Rader Resistin is an inflammatory marker of atherosclerosis in humans Circulation 111 2005 932 939
38. S. Chu, W. Ding, K. Li, Y. Pang, and C. Tang Plasma resistin associated with myocardium injury in patients with acute coronary syndrome Circ J 72 2008 1249 1253
39. N. Klöting, T.E. Graham, J. Berndt, S. Kralisch, P. Kovacs, and C.J. Wason Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass Cell Metab 6 2007 79 87
40. Q. Yang, T.E. Graham, N. Mody, F. Preitner, O.D. Peroni, and J.M. Zabolotny et al. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes Nature 436 2005 356 362
41. T.E. Graham, Q. Yang, M. Blüher, A. Hammarstedt, and T.P. Ciaraldi Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects N Engl J Med 354 2006 2552 2563
42. K.B. Goralski, and C.J. Sinal Type 2 diabetes and cardiovascular disease: getting to the fat of the matter Can J Physiol Pharmacol 85 2007 113 132
43. R.Z. Yang, M.J. Lee, H. Hu, J. Pray, H.B. Wu, and B.C. Hansen et al. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action Am J Physiol Endocrinol Metab 290 2006 E1253 E1261
44. C.M. De Souza Batista, R.Z. Yang, M.J. Lee, N.M. Glynn, D.Z. Yu, and J. Pray et al. Omentin plasma levels and gene expression are decreased in obesity Diabetes 56 2007 1655 1661
45. M.C. Ernst, and C.J. Sinal Chemerin: at the crossroads of inflammation and obesity Trends Endocrinol Metab 21 2010 660 667
46. T. Auguet, Y. Quintero, X. Terra, S. Martínez, and A. Lucas Upregulation of lipocalin 2 in adipose tissues of severely obese women: positive relationship with proinflammatory cytokines Obesity 19 2011 2295 2300
47. A. Nicolaou, S.E. Estdale, M. Tsatmali, D.P. Herrero, and A.J. Thody Prostaglandin production by melanocytic cells and the effect of alpha-melanocyte stimulating hormone FEBS Lett 570 2004 223 226
48. D.K. Lee, S.R. George, and B.F. O'Dowd Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity Trends Pharmacol Sci 27 2006 190 194
49. B. Telejko, M. Kuzmicki, N. Wawrusiewicz-Kurylonek, J. Szamatowicz, A. Nikolajuk, and A. Zonenberg et al. Plasma apelin levels and apelin/APJ mRNA expression in patients with gestational diabetes mellitus B Diabetes Res Clin Pract 87 2010 176 183
50. N. Klöting, J. Berndt, S. Kralisch, P. Kovacs, M. Fasshauer, and M.R. Schön et al. Vaspin gene expression in human adipose tissue: association with obesity and type 2 diabetes Biochem Biophys Res Commun 339 2006 430 436
51. J.K. Cho, T.K. Han, and H.S. Kang Combined effects of body mass index and cardio/respiratory fitness on serum vaspin concentrations in Korean young men Eur J Appl Physiol 108 2010 347 353
52. B.S. Youn, N. Klöting, J. Kratzsch, N. Lee, J.W. Park, and E.S. Song et al. Serum vaspin concentrations in human obesity and type 2 diabetes Diabetes 57 2008 372 377
53. Y. Ye, X.H. Hou, X.P. Pan, J.X. Lu, and W.P. Jia Serum vaspin level in relation to postprandial plasma glucose concentration in subjects with diabetes Chin Med J (Engl) 122 2009 2530 2533
54. D. Tripathy, P. Mohanty, S. Dhindsa, T. Syed, H. Ghanim, and A. Aljada et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects Diabetes 52 2003 2882 2887
55. B.B. Davidovici, N. Sattar, J.C. Prinz, and L. Puig Psoriasis and systemic inflammatory diseases: potencial mechanistic links between skin disease and co-morbid conditions J Invest Dermatol 130 2010 1785 1796
56. G.S. Hotamisligil, N.S. Shargill, and B.M. Spiegelman Adipose expression of tumor necrosis factor-alpha: direct role in obesitylinked insulin resistance Science 259 1993 87 91
57. P.A. Kern, M. Saghizadeh, J.M. Ong, R.J. Bosch, R. Deem, and R.B. Simsolo The expression of tumor necrosis factor in human adipose tissue regulation by obesity, weight loss, and relationship to lipoprotein lipase J Clin Invest 95 1995 2111 2119
58. G.S. Hotamisligil, P. Arner, J.F. Caro, R.L. Atkinson, and B.M. Spiegelman Increased adipose tissue expression of tumor necrosis factor alpha in human obesity and insulin resistance J Clin Invest 95 1995 2409 2415
59. H. Hauner, M. Bender, B. Haastert, and F. Hube Plasma concentrations of soluble TNF-alpha receptors in obese subjects Int J Obes Relat Metab Disord 22 1998 1239 1243
60. M. Kriegler, C. Perez, K. DeFay, I. Albert, and S.D. Lu A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF Cell 53 1988 45 53
61. S.P. Weisberg, D. Hunter, R. Huber, J. Lemieux, S. Slaymaker, and K. Vaddi et al. CCR2 modulates inflammatory and metabolic effects of high-fat feeding J Clin Invest 116 2006 115 124
62. S.E. Wozniak, L.L. Gee, M.S. Wachtel, and E.E. Frezza Adipose tissue: the new endocrine organ A review article Dig Dis Sci 54 2009 1847 1856
63. B. Wang, and P. Trayhurn Acute and prolonged effects of TNF-alpha on the expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture Pflugers Arch 452 2006 418 427
64. S. Galic, J.S. Oakhill, and G.R. Steinberg Adipose tissue as an endocrine organ Mol Cell Endocrinol 316 2010 129 139
65. G.S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance Science 271 1996 665 668
66. G.S. Hotamisligil, and B.M. Spiegelman Tumor necrosis factor alpha: a key component of the obesity-diabetes link Diabetes 43 1994 1271 1278
67. C.H. Lang, C. Dobrescu, and G.J. Bagby Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output Endocrinology 130 1992 43 52
68. H. Dominguez, H. Storgaard, C. Rask-Madsen, T. Steffen Hermann, N. Ihlemann, and D. Baunbjerg Nielsen et al. Metabolic and vascular effects of tumor necrosis factor-alpha blocked with etanercept in obese patients with type 2 diabetes J Vasc Res 42 2005 517 525
69. E. Maury, and S.M. Brichard Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome Mol Cell Endocrinol 314 2010 1 16
70. L.S. Tam, B. Tomlinson, T.T. Chu, T.K. Li, and E.K. Li Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis Clin Rheumatol 26 2007 1495 1498
71. E. Maury, K. Ehala-Aleksejev, Y. Guiot, R. Detry, A. Vandenhooft, and S.M. Brichard Adipokines oversecreted by omental adipose tissue in human obesity Am J Physiol Endocrinol Metab 293 2007 E656 E665
72. K. Eder, N. Baffy, A. Falus, and A.K. Fulop The major inflammatory mediator interleukin-6 and obesity Inflamm Res 58 2009 727 736
73. V. Mohamed-Ali, S. Goodrick, A. Rawesh, D.R. Katz, J.M. Miles, and J.S. Yudkin et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo J Clin Endocrinol Metab 82 1997 4196 4200
74. G. Sabio, M. Das, A. Mora, Z. Zhang, J.Y. Jun, and H.J. Ko et al. A stress signaling pathway in adipose tissue regulates hepatic insulin resistance Science 322 2008 1539 1543
75. L. Fontana, J.C. Eagon, M.E. Trujillo, P.E. Scherer, and S. Klein Visceral fat adipokine secretion is associated with systemic inflammation in obese humans Diabetes 56 2007 1010 1013
76. L. Mallbris, C.T. Ritchlin, and M. Stahle Metabolic disorders in patients with psoriasis and psoriatic arthritis Curr Rheumatol Res 8 2006 355 356
77. W. Sterry, B.E. Strober, and A. Menter Obesity in psoriasis: The metabolic, clinical and therapeutic implications Report of an interdisciplinary conference and review Br J Dermatol 157 2007 649 655
78. M. Wakkee, H.B. Thio, E.P. Prens, E.J. Sijbrands, and H.A. Neumann Unfavorable cardiovascular risk profiles in untreated and treated psoriasis patients Atherosclerosis 190 2007 1 9
79. G. Yosipovitch, A. DeVore, and A. Dawn Obesity and the skin: skin physiology and skin manifestations of obesity J Am Acad Dermatol 28 1993 901 916
80. L. Naldi, L. Chatenoud, D. Linder, A. Belloni Fortina, A. Peserico, and A.R. Virgili et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study J Invest Dermatol 125 2005 61 67
81. A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel, and J.M. Gelfand Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 2006 829 835
82. A.D. Cohen, M. Sherf, L. Vidavsky, D.A. Vardy, J. Shapiro, and J. Meyerovitch Association between psoriasis and the metabolic syndrome. A cross-sectional study Dermatology 216 2008 152 155
83. M.D. Herron, M. Hinckley, M.S. Hoffman, J. Papenfuss, C.B. Hansen, and K.P. Callis et al. Impact of obesity and smoking on psoriasis presentation and management Arch Dermatol 141 2005 1527 1534
84. D.M. Sommer, S. Jenisch, M. Suchan, E. Christophers, and M. Weichenthal Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis Arch Dermatol Res 298 2006 321 328
85. Y.J. Chen, C.Y. Wu, J.L. Shen, S.Y. Chu, C.K. Chen, and Y.T. Chang et al. Psoriasis independently associated with hyperleptinemia contributing to metabolic syndrome Arch Dermatol 144 2008 1571 1575
86. M.L. Murray, P.R. Bergstresser, B. Adams-Huet, and J.B. Cohen Relationship of psoriasis to obesity using same-gender siblings as controls for obesity Clin Exp Dermatol 34 2009 140 144
87. L. Mallbris, F. Granath, A. Hamsten, and M. Stahle Psoriasis is associated with lipid abnormalities at the onset of skin disease J Am Acad Dermatol 54 2006 614 621
88. S. Zamboni, G. Zanetti, G. Grosso, G.B. Ambrosio, S. Gozzetti, and A. Peserico Dietary behaviour in psoriatic patients Acta Derm Venereol Suppl (Stockh) 146 1989 182 183
89. R.D. Simons Additional studies on psoriasis in the tropics and in starvation camps J Invest Dermatol 12 1949 285 294
90. I. Rucevic, A. Perl, V. Barisic-Drusko, and M. Adam-Perl The role of the low energy diet in psoriasis vulgaris treatment Coll Antropol 27 2003 41 48
91. A.R. Setty, G. Curhan, and H.K. Choi Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses Health Study II Arch Intern Med 167 2007 1670 1675
92. J.M. Porres Jejunoileal bypass and psoriasis Arch Dermatol 113 1977 983
93. J.E. De Menezes Ettinger, E. Azaro, C.A. de Souza, P.V. dos Santos Filho, C.A. Mello, and M. Neves Jr. et al. Remission of psoriasis after open gastric bypass Obes Surg 16 2006 94 97
94. G. Higa-Sansone, S. Szomstein, F. Soto, O. Brasecsco, C. Cohen, and R.J. Rosenthal Psoriasis remission after laparoscopic rouxen-Y gastric bypass for morbid obesity Obes Surg 14 2004 1132 1134
95. Y. Jin, F. Zhang, S. Yang, and Y. Kong Combined effects of HLA-Cw6, body mass index and waist-hip ratio on psoriasis vulgaris in Chinese Han population J Dermatol Sci 52 2008 123 129
96. E.A. Hamminga, A.J. van der Lely, H.A.M. Neumann, and H.B. Thio Chronic inflammation in psoriasis and obesity: implications for therapy Med Hypotheses 67 2006 768 773
97. H.H. Roenigk Jr., R. Auerbach, H. Maibach, G. Weinstein, and M. Lebwohl Methotrexate in psoriasis: consensus conference J Am Acad Dermatol 38 1998 478 485
98. G. Langman, P.M. Hall, and G. Todd Role of non-alcoholic steatohepatitis in methotrexate-induced liver injury J Gastroenterol Hepatol 16 2001 1395 1401
99. M.A. Berends, J. Snoek, E.M. de Jong, P.C. van de Kerkhof, M.G. van Oijen, and J.H. van Krieken et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent Aliment Pharmacol Ther 24 2006 805 811
100. D.A. Malatjalian, J.B. Ross, C.N. Williams, S.J. Colwell, and B.J. Eastwood Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up Can J Gastroenterol 610 1996 369 375
101. H. Montaudié, E. Sbidian, C. Paul, A. Maza, A. Gallini, and S. Aractingi et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity J Eur Acad Dermatol Venereol 25 2011 12 18
102. G. Weinstein, H. Roenigk, H. Maibach, J. Cosmides, K. Halprin, and M. Millard Psoriasis-liver-methotrexate interactions Arch Dermatol 108 1973 36 42
103. H.H. Roenigk Jr., W.F. Bergfeld, R. St Jacques, F.J. Owens, and W.A. Hawk Hepatotoxicity of methotrexate in the treatment of psoriasis Arch Dermatol 103 1971 250 261
104. P. Rosenberg, H. Urwitz, A. Johannesson, A.M. Ros, J. Lindholm, and N. Kinnman et al. Psoriasis patients with diabetes type 2 are at high risk of developing liver fibrosis during methotrexate treatment J Hepatol 46 2007 1111 1118
105. H.H. Roenigk Jr., R. Auerbach, H.I. Maibach, and G.D. Weinstein Methotrexate guidelines-revised J Am Acad Dermatol 6 1982 145 155
106. R. Micha, F. Imamura, M. Wyler von Ballmoos, D.H. Solomon, M.A. Hernán, and P.M. Ridker et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease Am J Cardiol 108 2011 1362 1370
107. R.M. Merion, A.M. Twork, L. Rosenberg, J.M. Ham, G.D. Burtch, and J.G. Turcotte et al. Obesity and renal transplantation Surg Gynecol Obstet 172 1991 367 376
108. G.C. Yee, T.R. McGuire, D.J. Gmur, T.P. Lennon, and H.J. Deeg Blood cyclosporine pharmacokinetics in patients undergoing marrow transplantation: influence of age, obesity, and hematocrit Transplantation 46 1988 399 402
109. N. Shibata, T. Hayakawa, N. Hoshino, T. Minouchi, A. Yamaji, and M. Uehara Effect of obesity on cyclosporine trough concentrations in psoriasis patients Am J Health Syst Pharm 55 1998 1598 1602
110. A. Maza, H. Montaudié, E. Sbidian, A. Gallini, S. Aractingi, and F. Aubin et al. Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis J Eur Acad Dermatol Venereol 25 2011 19 27
111. D. Thaçi, M. Bräutigam, R. Kaufmann, G. Weidinger, C. Paul, and E. Christophers Body-weight-indepent dosing of cyclosporine micro-emulsion and three times weekely maintenance regimen in severe psoriasis. A randomised study Dermatology 205 2002 383 388
112. P. Gisondi, M. Del Giglio, V. Di Francesco, M. Zamboni, and G. Girolomoni Weight loss importes the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigador-blinded clinical trial Am J Clin Nutr 88 2008 1242 1247
113. V. Garcia-Patos Tratamiento sistémico de acitetrina, metotrexato y ciclosporina Temas en psoriasis 2005 DNA Health, SL Madrid p. 136-49
114. S. Corbetta, R. Angioni, A. Cattaneo, P. Beck-Peccoz, and A. Spada Effects of retinoid therapy on insulin sensitivity, lipid profile and circulating adipocytokines Eur J Endocrinol 154 2006 83 86
115. L. Clark, and M. Lebwohl The effect of weight on the efficacy of biologic therapy in patients with psoriasis J Am Acad Dermatol 58 2008 443 446
116. L. Puig Obesity and psoriasis: body weight and body mass index influence the response to biological treatment J Eur Acad Dermatol Venereol 25 2011 1007 1011
117. S.A. Ritchie, and J.M. Connell The link between abdominal obesity, metabolic syndrome and cardiovascular disease Nutr Metab Cardiovasc Dis 17 2007 319 326
118. L. Naldi, A. Addis, S. Chimenti, A. Giannetti, M. Picardo, and C. Tomino et al. Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis Dermatology 217 2008 365 373
119. K. Reich, A.B. Gottlieb, A. Kimball, and S. Li Consistency of infliximab response across subgroups of patients with psoriasis: integrated results from randomized controlled clinical trials J Am Acad Dermatol 54 2006 AB215
120. A.A. Duarte Moderate to severe psoriasis treated with infliximab-53 patients: patients profile, efficacy and adverse effects An Bras Dermatol 86 2011 257 263
121. B. Strober, A. Gottlieb, C. Leonardi, and K. Papp Levels of response of psoriasis patients with different baseline characteristics treated with etanercept J Am Acad Dermatol 54 2006 AB220
122. K. Gordon, N. Korman, E. Frankel, H. Wang, A. Jahreis, and R. Zitnik et al. Efficacy of etanercept in an integrated multistudy database of patients with psoriasis J Am Acad Dermatol 54 2006 S101 S111
123. M. Esposito, A. Mazzotta, R. Saraceno, C. Schipani, and S. Chimenti Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis Int J Immunopathol Pharmacol 22 2009 219 225
124. M. De Groot, M. Appelman, P.L. Spuls, M.A. de Rie, and J.D. Bos Initial experience with routine administration of etanercept in psoriasis Br J Dermatol 155 2006 808 814
125. A. Menter, K. Gordon, O. Goldblum, and Y. Gu Efficacy and safety of adalimumab are consistent across weight quartiles in patients with moderate to severe psoriasis: subanalysis of REVEAL J Am Acad Dermatol 60 2009 AB173
126. A. Menter, K.B. Gordon, C.L. Leonardi, Y. Gu, and O.M. Goldblum Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis J Am Acad Dermatol 63 2010 448 456
127. K. Kragballe, A. Sygehus, D. Thaçi, K. Unnebrink, and O. Goldblum Adalimumab plus topical treatment (calcipotriol/betamethasone) in the treatment of moderate to severe psoriasis: response across subgroups in BELIEVE J Am Acad Dermatol 62 Suppl 1 2010 AB133
128. J.H. Saurat, K. Unnebrik, O. Golblum, and R. Bissonnette Adalimumab response is consistent across subgroups of patients with moderate to severe psoriasis: subanalysis of the CHAMPION study J Am Acad Dermatol 62 2010 AB124
129. M.S. Young, E.J. Horn, and J.C. Cather The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients Expert Rev Clin Immunol 7 2011 9 13
130. A.M.R. Downs Switching between antitumour necrosis factor alpha biologic agents-is patient weight an important consideration Br J Dermatol 160 2009 1123 1124
131. M. Papoutsaki, M.S. Chimenti, A. Costanzo, M. Talamonti, A. Zangrilli, and A. Giunta et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics J Am Acad Dermatol 57 2007 269 275
132. M.H. Weisman, L.W. Moreland, D.E. Furst, M.E. Weinblatt, E.C. Keystone, and H.E. Paulus et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid artritis receiving concomitant methotrexate: a pilot study Clin Ther 25 2003 1700 1721
133. M. Lebwohl, N. Yeilding, P. Szapary, Y. Wang, S. Li, and Y. Zhu et al. Impact of weight on the efficacy and safety of ustekinumab in patients with moderate to severe psoriasis: rationale for doping recommendations J Am Acad Dermatol 63 2010 571 579
134. R. Saraceno, C. Schipani, A. Mazzotta, M. Esposito, L. Di Renzo, and A. De Lorenzo et al. Effect of anti-tumor necrosis factoralpha therapies on body mass index in patients with psoriasis Pharmacol Res 57 2008 290 295
135. C. Grunfeld, C. Zhao, J. Fuller, A. Pollack, A. Moser, and J. Friedman et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters J Clin Invest 97 1996 2152 2157
136. T.G. Kirchgessner, K.T. Uysal, S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil Tumor necrosis factor-alpha contributes to obesity-related hyperleptinemia by regulating leptin release from adipocytes J Clin Invest 100 1997 2777 2782
137. M.M. Farías, V. Serrano, and C. de la Cruz Psoriasis y obesidad: revisión y recomendaciones prácticas Actas Dermosifiliogr 102 2011 505 509
138. E. Daudén, S. Castañeda, C. Suárez, J. García-Campayo, A.J. Blasco, M.D. Aguilar Grupo de Trabajo en Comorbilidades asociadas a la Psoriasis Abordaje integral de la comorbilidad en los pacientes con psoriasis Actas Dermosifiliogr 103 Suppl 1 2012 1 64